Skip to content

13F-HR filed by BB BIOTECH AG

BB BIOTECH AG filed this 13F-HR for the quarter ended 2015-06-30, filed 2015-08-12, with 29 holding rows worth $3,688,934,000.

Accession
0000950123-15-008623
Filed
2015-08-12
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q2 2015

A holdings report, 29 entries on the cover page, a total value of $3,688,934,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $3,688,933,000 with VALUE read as thousands by filing date, 13F file number 028-06964. The quarter's positions are built on this report. The resolved quarter.

Other managers

  • included managerBiotech Focus N.V. 028-11193
  • included managerBiotech Invest N.V. 028-11191
  • included managerBiotech Target N.V. 028-11189
  • included managerBiotech Growth N.V. 028-11194

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
CELGENE CORP151020104COM3,564,298$412,514,000thousands by filing date
INCYTE CORP COM45337C102Stock3,740,406$389,788,000thousands by filing date
ISIS PHARMACEUTICALS INC464330109COM5,929,426$341,238,000thousands by filing date
Gilead Sciences,Inc.375558103COM2,715,596$317,942,000thousands by filing date
RADIUS HEALTH INC750469207COM NEW3,922,140$265,529,000thousands by filing date
AGIOS PHARMACEUTICALS INC00847X104COM1,989,921$221,160,000thousands by filing date
Vertex Pharmaceuticals Incorporated92532F100COM1,334,445$164,777,000thousands by filing date
NEUROCRINE BIOSCIENCES INC64125C109COM3,221,552$153,861,000thousands by filing date
MEDIVATION INC58501N101COM1,290,556$147,381,000thousands by filing date
ALEXION PHARMACEUTICALS INC015351109COM777,428$140,536,000thousands by filing date
HALOZYME THERAPEUTICS INC COM40637H109Stock6,077,168$137,222,000thousands by filing date
RECEPTOS, INC.756207106COMMON STOCK665,272$126,435,000thousands by filing date
ALNYLAM PHARMACEUTICALS INC COM02043Q107Stock965,499$115,734,000thousands by filing date
REGENERON PHARMACEUTICALS COM75886F107Stock198,000$101,006,000thousands by filing date
NOVAVAX INC670002104COMMON STOCK8,180,000$91,125,000thousands by filing date
TETRAPHASE PHARMACEUTICALS INC88165N105COMMON STOCK1,507,114$71,497,000thousands by filing date
ALDER BIOPHARMACEUTICALS INC014339105COM1,155,150$61,188,000thousands by filing date
PUMA BIOTECHNOLOGY INC74587V107COMMON STOCK521,991$60,942,000thousands by filing date
CEMPRA INC15130J109COM1,766,900$60,711,000thousands by filing date
PTC THERAPEUTICS INC69366J200COM1,252,912$60,303,000thousands by filing date
CLOVIS ONCOLOGY INC189464100COM618,188$54,326,000thousands by filing date
TESARO INC881569107COM904,582$53,180,000thousands by filing date
INTERCEPT PHARMACEUTICALS IN45845P108COM180,719$43,622,000thousands by filing date
INFINITY PHARMACEUTICALS INC45665G303COM2,700,737$29,573,000thousands by filing date
JUNO THERAPEUTICS INC48205A109COM450,000$23,999,000thousands by filing date
KITE PHARMA INC49803L109COM350,000$21,340,000thousands by filing date
ACHILLION PHARMACEUTICALS IN00448Q201COM1,279,340$11,335,000thousands by filing date
THERAVANCE INC88338T104COMMON STOCK331,594$5,992,000thousands by filing date
THERAVANCE BIOPHARMA INCG8807B106COM359,190$4,677,000thousands by filing date

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0000950123-15-008623this filing2015-08-12acceptance time not in the bulk data set